Leveraging Data to Improve Clinical Care
Goshua Lab at Yale School of Medicine
Our Collaborators
We are the spoke of a collaborative research hub that include experts from leading health care institutions around the world.
.png)
Aligning Clinical Diagnostic and Treatment Strategies with Conventional and Distributional Value to Improve Health Care Performance
The US continues to rank #1/11 in health care spending and #11/11 in healthcare performance. We consistently pay more for less health. The Goshua Lab fuses state-of-the-art in quantitative decision science with clinical expertise to address this value lost, with a particular focus on hematologic-oncologic diseases. Our analytic lens includes both conventional value (i.e., cost-benefit) and distributional impact (i.e., socioeconomic status, geographic region) analyses to inform stakeholders’ decision-making on resource allocation in health care.
Our Work
Source: Mirror, Mirror 2021: Reflecting Poorly, The Commonwealth Fund
Selected Recognitions
Our work has been recognized by premier national organizations and conferences
#1
Most cited original research manuscript in
The Lancet Hematology (>1,000 citations)
20
Oral Presentations
(17 ASH, 1 EHA, 2 SMDM)
#1
Trending manuscript globally on PubMed (Blood)
3
ASH Press Program Selections
(from >5000 abstracts)
Cost-effectiveness of ferritin screening thresholds for iron deficiency in reproductive-age women
Wang D, Sra M, Glaeser-Khan S, Wang DY, Moshashaian-Asl R, Ito S, Cuker A, Goshua G
American Journal of Hematology
2025
April
FEATURED
Cost-effectiveness of iptacopan for paroxysmal nocturnal hemoglobinuria
Ito S*, Chetlapalli K*, Wang D, Potnis KC, Richmond R, Krumholz H, Lee AI, Cuker A, Goshua G.
Blood
2025
January
FEATURED
Cost-effectiveness of bevacizumab in the care of patients with hereditary hemorrhagic telangiectasia
Wang D, Ito S, Waldron C, Butt A, Zhang E, Krumholz HM, Al-Samkari H, Goshua G.
Blood Advances
2024
June
FEATURED
Gap: Decreasing the need for hospital, emergency, and procedural care with the use of bevacizumab (vs no bevacizumab) improves quality-adjusted life expectancy and saves costs in the care of people living with HHT (MGH-Yale collaboration). ASH Abstract Achievement Award, Best of ASH (HTRS) (D. Wang)
Prophylactic weekly efanesoctocog alfa versus standard-care factor VIII in people living with severe hemophilia A: a cost-effectiveness analysis
Ito S, Potnis KC, Harvey JP, Sra M, Bewersdorf JP, Bona RD, Krumholz HM, Cuker A, Pandya A, Goshua G
Annals of Internal Medicine
2025
April
FEATURED
Decreasing alloimmunization-specific mortality in sickle cell disease in the United States: Cost-effectiveness of a shared transfusion resource
American Journal of Hematology
2024
April
FEATURED
Gap: Supporting the mission of the 501(c)(3) Alloantibody Exchange www.alloantibody.org. 2022 ASH Press Program Selection.
